Efficacy of etrasimod at Week 52 among patients with clinical response at Week 12 compared with the overall ulcerative colitis population: post hoc analysis of the phase 3 ELEVATE UC 52 trial

Introduction Etrasimod is an investigational, oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). The phase 3 ELEVATE UC 52 trial (NCT03945188) comprised a 12-week (wk) induction period followed by a 40-wk maintenance period with a treat-through design (maintenance efficacy evaluated in all patients [pts] randomised from baseline), [1] in contrast with UC clinical trials using responder re-randomisation designs (maintenance efficacy only evaluated in pts with clinical response at induction period end).[2]